[Click eStock] "LaMeditech, Laser Platform Technology in Focus"

Kiwoom Securities analyzed on the 30th that it is time to pay attention to the high scalability of the laser platform of RamediTech.

Hyunjin Oh, a researcher at Kiwoom Securities, explained, "RamediTech possesses not only core technology for laser miniaturization but also device design and manufacturing technology," adding, "It has product competitiveness through high entry barriers and potential for various business expansions."

He continued, "In addition to the only laser-based home care beauty device, Purasel-ME, the professional skincare device Purasel-MX, equipped with seven functions including fractional laser capabilities, is expected to have high demand based on strong price competitiveness."

Researcher Oh noted, "We also pay attention to the Original Design Manufacturing (ODM) business for beauty devices," analyzing, "They have supplied scalp care devices to global distributors and can collaborate with cosmetic companies for developing beauty devices that maximize cosmetic absorption." Furthermore, he emphasized, "We expect expansion into the bio sector through the development of laser drug delivery systems," and added, "It is understood that they recently signed an MOU for next-generation drug development based on the laser platform with new drug development companies."

Researcher Oh explained, "RamediTech's stock price has fallen more than 20% compared to the public offering price," and said, "The additional impact due to the release of lock-up shares is expected to be limited." He added, "It is a time to focus on the growth potential of the platform business based on ultra-small laser core technology."